Ashley Gallagher, Editor

Spherix Global Insights estimates that SER-109 (Seres Therapeutics; Aimmune) will be able to challenge fecal microbiota, live-jslm in C. difficile treatment.

Phase 2B clinical trial results demonstrate that patients experienced improvement in total body and facial repigmentation.

Children in the LT-001 study treated after onset achieved or maintained additional milestones up to 7.5 years after 1-time intravenous infusion, Novartis says.

Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.

The test did not reach the World Health Organization’s minimum performance requirement, which is 80% sensitivity for SARS-CoV-2, in the study population.

In an additional post-hoc analysis, guselkumab demonstrated improvements at week 48, according to Janssen Pharmaceutical.

The treatment shows positive results in metastasis-free survival for men with non-metastatic hormone-sensitive prostate cancer, Pfizer and Astellas announce.

Retifanlimab-dlwr (Zynyz; Incyte) was granted FDA accelerated approval for metastatic or recurrent locally advanced Merkel cell carcinoma.

The primary outcome of the study includes an IGA score of 0 or 1, which indicated clear or almost clear skin, respectively, with a reduction, from baseline to week 16.

Blinded arms of the study will continue to evaluate the combination therapy with docetaxel vs docetaxel alone, Merck says.

Purine metabolite xanthine, found in caffeinated beverages and food, affect cell differentiation, and new study results may lead to more knowledge about why diseases such as IBD develop.

Investigators estimate that the effectiveness was higher after 1 or 2 booster doses compared with the primary series alone.

MenABCWY combination meets all 11 primary endpoints and shows that it is well tolerated, with a safety profile consistent with MenACWY (Menveo) and MenB (Bexsero).

Rivaroxaban and aspirin results in a 33% reduction in major adverse limb events both early and late following lower extremity revascularization.

Trastuzumab deruxtecan from AstraZeneca and Daiichi Sankyo meets prespecified criteria for duration of response and objective response rate.

The changes, which will be effective January 1, 2024, include pre-filled pens, vials of basal, vials of bolus, and pre-mix insulins.

Study includes healthy individuals and those who had progressive multiple sclerosis with the nasally administered treatment.

The COVID-19 pandemic was associated with an increase in rural-urban telemedicine divide across the Veteran Affairs health care system.

Eli Lilly treatment targets soluble amyloid beta and did not clear plaque or halt accumulation of amyloid in individuals treated with the drug in the A4 study.

These infections can include the central nervous system (CNS), circulation, invaded organs, lower airway, and the middle ear, with outcomes that can be permanent.

The application is based on phase 3 results from the DINAMO trial showing that Jardiance tablets significantly reduced A1C levels vs a placebo in participants aged 10 to 17 years.

More than 300,000 individuals in the United States have CSU that is inadequately controlled by antihistamines.

Including probiotics and antibiotics, such as fidaxomicin and vancomycin, could help prevent CDI, but more research is needed to evaluate them, investigators say.

Therapy consists of high-dose abatacept, ruxolitinib, and proactive monitoring for respiratory muscle involvement.

Study results indicates that the injectable antiretroviral therapy can benefit patients who are historically underserved and may face treatment barriers, including those with mental illness.

Companies seek FDA approval for individuals aged 12 years and older to receive vaccinations for their primary series.

Zavegepant is the first calcitonin gene-related peptide receptor for migraines in development as an intranasal formulation studied in a phase 3 trial.

Phase 3 trial results indicate efficacy against respiratory syncytial virus-lower respiratory tract disease in individuals aged 60 years and older.

Data show continued objective response rate, overall survival, and progression-free survival benefits of nivolumab plus cabozantinib in the treatment of advanced renal cell carcinoma.

Findings highlight the need for evidence-based strategies to avoid being obese or overweight for patients with type 1 diabetes, which is often considered a disease of thin individuals.